Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results

• Interim results of a Phase 1b trial of cirmtuz umab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast cancer compare favorably to historical single-agent paclitaxel data (57% ORR vs. ~30% ORR historical single-agent paclitaxel)

• In a preclinical study of cirmtuzumab added to high-grade serous ovarian cancer cell lines, cirmtuzumab demonstrated single agent activity and enhanced the anti-proliferative effect of commonly used chemotherapies

• Oncternal appointed Chase Leavitt as General Counsel

• Oncternal presenting clinical updates on cirmtuzumab in MCL/CLL and TK216 in Ewing sarcoma at the ASCO Annual Meeting in June 2021

• Management to host webcast today at 5:00 pm ET

https://investor.oncternal.com/news-releases/news-release-details/oncternal-provides-business-update-and-announces-first-quarter-0